2018
Evidence supporting the best clinical management of patients with multimorbidity and polypharmacy: a systematic guideline review and expert consensus
Muth C, Blom JW, Smith SM, Johnell K, Gonzalez‐Gonzalez A, Nguyen TS, Brueckle M, Cesari M, Tinetti M, Valderas JM. Evidence supporting the best clinical management of patients with multimorbidity and polypharmacy: a systematic guideline review and expert consensus. Journal Of Internal Medicine 2018, 285: 272-288. PMID: 30357955, DOI: 10.1111/joim.12842.Peer-Reviewed Original ResearchConceptsGuideline reviewReview of medicationsCoordination of careHeterogeneity of patientsBetter clinical managementSelf-management issuesRisk prediction modelAriadne principlesMedication appropriatenessInformational continuityTreatment optionsMedical historyPatient preferencesClinical managementPsychosocial assessmentTreatment benefitCare planningCare plansMultimorbidityFeasible interventionExpert consensusHealthcare providersPatientsClinical decisionPolypharmacy
2015
Association between guideline recommended drugs and death in older adults with multiple chronic conditions: population based cohort study
Tinetti ME, McAvay G, Trentalange M, Cohen AB, Allore HG. Association between guideline recommended drugs and death in older adults with multiple chronic conditions: population based cohort study. The BMJ 2015, 351: h4984. PMID: 26432468, PMCID: PMC4591503, DOI: 10.1136/bmj.h4984.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCause of DeathChronic DiseaseComorbidityDrug PrescriptionsFemaleHumansInterviews as TopicMaleMedicarePractice Guidelines as TopicSurvival AnalysisUnited StatesConceptsSerotonin-norepinephrine reuptake inhibitorsMultiple chronic conditionsSelective serotonin reuptake inhibitorsAdjusted hazard ratioRisk of deathCalcium channel blockersChronic conditionsHazard ratioΒ-blockersCohort studyReuptake inhibitorsAtrial fibrillationOlder adultsChannel blockersCardiovascular drugsSSRIs/serotonin-norepinephrine reuptake inhibitorsRenin-angiotensin system blockersNorepinephrine reuptake inhibitorsSerotonin reuptake inhibitorsCommon combinationRAS blockersSystem blockersStudy drugHeart failureThromboembolic disease